Please assess the completion status of the following clinical trial:

Trial Title: Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:All of below~1. Patient must have the ability to understand and sign a written informed consent form; consent must be obtained prior to initiation of study procedures~2. Male or female, 20 to 80 years of age~3. Compensated liver disease (Child-Pugh score \< 8)~4. HBsAg positive at least 6 months or more~5. HBeAg positive or negative~6. Confirmation of ETV resistance mutation (rt184, rtS202, or rtM250) at the enrollment of IN-US-174-0202 study, or ADV resistance mutation (rtA181V, rtA181T or rtN236T) at the enrollment of IN-US-174-0205 study~7. Completion of the week 240 visit in studies IN-US-174-0202 or 0205 study and maintained on TDF 300 mg QD~8. Patient is willing and able to comply with all study requirements~Exclusion Criteria: Any of below~1. Co-infection with HCV, HDV, HIV~2. Abusing alcohol (more than 40 g/day) or illicit drugs~3. Abnormal hematological and biochemical parameters, including:~1) serum bilirubin \>3 mg/dL 2) prothrombin time (INR) \>1.5 3) serum albumin \<2.8 g/dL 4) ascites, encephalopathy or variceal hemorrhage 5) Child-Pugh score ≥8~4. Received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study~5. Medical condition that requires concurrent use of systemic corticosteroid or other immunosuppressive agent~6. Received solid organ or bone marrow transplant~7. Known hypersensitivity to study drugs, metabolites, or formulation excipients~8. Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the patient unsuitable for the study or unable to comply with dosing requirements~9. Use of investigational agents within 3 months of screening, unless allowed by the Sponsor or Investigator~10. A history of hepatocellular carcinoma (HCC) within 5 years of screening~11. A history treated malignancy (other than HCC) is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding three years~12. Participation in another investigational drug trial~13. Pregnant or breastfeeding or willing to be pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Maintaining TAF monotherapy (Type: EXPERIMENTAL): - Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 96 weeks
- Switching from TDF to TAF (Type: ACTIVE_COMPARATOR): * Tenofovir Disoproxil Fumarate (Viread) Tablet, 300mg, Daily Oral, 48 weeks~* Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).